跳至主要内容
临床试验/IRCT2016040919912N2
IRCT2016040919912N2已完成未知

Evaluation the effect of squill oxymel, Traditional Medicine product, in the treatment of chronic obstructive pulmonary disease (COPD) in patients 18 to 60 years old: triple-blind randomized Clinical trial

Tehran University of Medical Sciences0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Age 18 to 60 years; patients with GOLD stage IIA COPD who have clinical criteria include: FEV1/FVC less than 0.7 of the predicted and FEV1 between 50% to 80% of the predicted; treated with conventional drugs; Lack of pregnancy; Lack of breastfeeding; Lack of the use other herbal medicines; Lack of active peptic ulcer and cardiovascular disease (especially heart block) or renal disease; Not concomitant use of anticoagulant; Non-smoking. Exclusion criteria: Add or remove the drugs that interferes with COPD (such as NSAIDs); Infections leading to hospitalization; the patient's unwillingness to continue treatment.

排除标准

  • 未提供

研究者

相似试验